A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Paulette Mattson
- Phone Number: 651-675-0300
- Email: pmattson@hibercell.com
Study Contact Backup
- Name: Michele Gargano
- Phone Number: 651-675-0300
- Email: mgargano@hibercell.com
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- Recruiting
- University of Arizona Cancer Center
-
Contact:
- Luis Rivera
- Email: Lrivera2@arizona.edu
-
-
California
-
La Jolla, California, United States, 92093
- Recruiting
- University of California San Diego Moores Cancer Center
-
Contact:
- Karen Cuervo
- Email: kcuervo@health.ucsd.edu
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center
-
Contact:
- Allison Bautista
- Email: Allison.Bautista@cshs.org
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Anschutz Medical Campus
-
Contact:
- Elaine Lam, MD
- Email: elaine.lam@cuanschutz.edu
-
Lone Tree, Colorado, United States, 80124
- Recruiting
- Rocky Mountain Cancer Centers, LLP
-
Contact:
- Jennifer Hege
- Email: jennifer.hege@usoncology.com
-
Contact:
- Annie Sauve
- Email: Annie.Sauve@usoncology.com
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale - New Haven Hospital
-
Contact:
- David Schoenfeld, MD
- Email: david.schoenfeld@yale.edu
-
Contact:
- Chioma Amenechi
- Email: chioma.amenechi@yale.edu
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Withdrawn
- Karmanos Cancer Institute
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55101
- Recruiting
- HealthPartners Cancer Research Center
-
Contact:
- Octav Pacurar
- Email: Octav.Pacurar@ParkNicollet.com
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- Melissa Reimers, MD
- Email: mreimers@wustl.edu
-
Contact:
- Jessica Klette
- Email: j.klette@wustl.edu
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Kira vom Eigen
- Email: vomeigek@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospitals Cleveland Medical Center
-
Contact:
- Gina Wick
- Email: Gina.Wick@UHhospitals.org
-
Contact:
- Lindsay Spiker
- Email: Lindsay.Spiker@uhhospitals.org
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Christina Dempsey
- Email: DEMPSEC2@ccf.org
-
Contact:
- Ireland Flores Rae
- Email: floresi@ccf.org
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Active, not recruiting
- Providence Cancer Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Institute (SCRI)
-
Contact:
- Amber Cox
- Email: Amber.Cox@scri.com
-
Contact:
- Alexis Daniel
- Email: alexis.daniel@scri.com
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- University of Texas Southwestern Medical Center
-
Contact:
- Hans Hammers, MD
- Email: Hans.Hammers@utsouthwestern.edu
-
Contact:
- Jennnifer Bloxham
- Email: Jennifer.Bloxham@utsouthwestern.edu
-
Dallas, Texas, United States, 75246
- Recruiting
- Texas Oncology
-
Contact:
- Sarah Shipley
- Email: sarah.shipley@usoncology.com
-
Lubbock, Texas, United States, 79430
- Recruiting
- University Medical Center & Texas Tech Health Science Center
-
Contact:
- Mariana Fiori
- Email: Mariana.Fiori@ttuhsc.edu
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Virginia Cancer Specialists
-
Contact:
- Karina Castillo Grady
- Phone Number: 571-350-8758
- Email: karina.castillogrady@usoncology.com
-
Contact:
- Nicolas Rojas
- Email: Nicolas.Rojas2@usoncology.com
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Fred Hutchinson Cancer Center
-
Contact:
- Scott Tykodi, MD
- Email: stykodi@fredhutch.org
-
Contact:
- Jennifer Hanneld Cooper
- Email: jhcooper@fredhutch.org
-
Seattle, Washington, United States, 98104
- Recruiting
- Swedish Medical Center
-
Contact:
- Kallie Sorenson
- Email: Kallie.Sorenson@Swedish.org
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- Recruiting
- University of Wisconsin - Carbone Cancer Center
-
Contact:
- Ellie Dahms
- Email: edahms@wisc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component
- Be age 18 years or older (male or female) at the time of consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Monotherapy
Participants will receive HC-7366 monotherapy [dose to be determined] daily |
HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator. |
|
Experimental: Combination
Participants will receive HC-7366 monotherapy [dose to be determined] in combination with belzutifan [120 mg] daily |
HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator. Belzutifan is a potent and selective HIF-2α inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determination of MTD and RP2D (combination cohorts only)
Time Frame: 30 months
|
To identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability and dose-limiting toxicities (DLTs) of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology irrespective of VHL gene mutation status |
30 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Neoplastic Processes
- Urologic Neoplasms
- Carcinoma
- Pathological Conditions, Signs and Symptoms
- Neoplasm Metastasis
- Carcinoma, Renal Cell
- Kidney Neoplasms
- belzutifan
Other Study ID Numbers
Other Study ID Numbers
- HC366-RCC2311
- MK-6482-030 (Other Identifier: Merck Sharp & Dohme LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.